Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTTR
Previous Symbol
CUSIPN/A
Phone310-203-1000
Debt
Debt-to-Equity RatioN/A
Current Ratio5.08
Quick Ratio5.08
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$3.03 per share
Price / Book0.26
Profitability
EPS (Most Recent Fiscal Year)($5.00)
Net Income$-7,860,000.00
Net MarginsN/A
Return on Equity-131.51%
Return on Assets-84.58%
Miscellaneous
Employees9
Outstanding Shares5,730,000
Market Cap$4.53 million
OptionableNot Optionable
Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions
What is Ritter Pharmaceuticals' stock symbol?
Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."
When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?
Ritter Pharmaceuticals's stock reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Ritter Pharmaceuticals' earnings last quarter?
Ritter Pharmaceuticals Inc (NASDAQ:RTTR) announced its quarterly earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.56) by $0.15. View Ritter Pharmaceuticals' Earnings History.
When is Ritter Pharmaceuticals' next earnings date?
What price target have analysts set for RTTR?
1 analysts have issued 12 month price targets for Ritter Pharmaceuticals' stock. Their forecasts range from $15.00 to $15.00. On average, they anticipate Ritter Pharmaceuticals' share price to reach $15.00 in the next year. This suggests a possible upside of 1,798.7% from the stock's current price. View Analyst Price Targets for Ritter Pharmaceuticals.
What is the consensus analysts' recommendation for Ritter Pharmaceuticals?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ritter Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ritter Pharmaceuticals.
What are Wall Street analysts saying about Ritter Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ritter Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. " (11/16/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We maintain our Buy rating and $4.30. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, topsalysin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (8/15/2018)
Has Ritter Pharmaceuticals been receiving favorable news coverage?
Headlines about RTTR stock have trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the next several days.
Who are some of Ritter Pharmaceuticals' key competitors?
Some companies that are related to Ritter Pharmaceuticals include Onconova Therapeutics (ONTX), Pain Therapeutics (PTIE), Aileron Therapeutics (ALRN), Genprex (GNPX), Kaya (KAYS), Pulmatrix (PULM), Sunwin Stevia International (SUWN), SUMMIT THERAPEU/S (SMMT), Capricor Therapeutics (CAPR), THERAPIX BIOSCI/S (TRPX), ESSA Pharma (EPIX), Soligenix (SNGX), MusclePharm (MSLP), KITOV PHARMA LT/S (KTOV) and Sunesis Pharmaceuticals (SNSS).
Who are Ritter Pharmaceuticals' key executives?
Ritter Pharmaceuticals' management team includes the folowing people:
- Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 35)
- Mr. Michael D. Step, Consultant & Director (Age 58)
- Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 58)
- Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)
- Ms. Robin Schmidt, Director of Clinical Operations
When did Ritter Pharmaceuticals IPO?
(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.
Who are Ritter Pharmaceuticals' major shareholders?
Ritter Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc (0.98%). Company insiders that own Ritter Pharmaceuticals stock include Matthew W Foehr and Michael D Step. View Institutional Ownership Trends for Ritter Pharmaceuticals.
Which institutional investors are buying Ritter Pharmaceuticals stock?
RTTR stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. Company insiders that have bought Ritter Pharmaceuticals stock in the last two years include Matthew W Foehr and Michael D Step. View Insider Buying and Selling for Ritter Pharmaceuticals.
How do I buy shares of Ritter Pharmaceuticals?
Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ritter Pharmaceuticals' stock price today?
One share of RTTR stock can currently be purchased for approximately $0.79.
How big of a company is Ritter Pharmaceuticals?
Ritter Pharmaceuticals has a market capitalization of $4.53 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe.
What is Ritter Pharmaceuticals' official website?
How can I contact Ritter Pharmaceuticals?
Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]
MarketBeat Community Rating for Ritter Pharmaceuticals (NASDAQ RTTR)
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
